# A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects

> **NCT03304964** · PHASE1 · COMPLETED · sponsor: **Foresee Pharmaceuticals Co., Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** FP-025 (MMP-12 inhibitor)
- **DRUG:** FP-025 (MMP-12 inhibitor)
- **DRUG:** FP-025 (MMP-12 inhibitor)
- **DRUG:** FP-025 (MMP-12 inhibitor)
- **DRUG:** FP-025 (MMP-12 inhibitor)

## Key facts

- **NCT ID:** NCT03304964
- **Lead sponsor:** Foresee Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-21
- **Primary completion:** 2018-06-01
- **Final completion:** 2018-07-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03304964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03304964, "A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03304964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*